SYK Stock Stryker Corporation
BUY US · NYSERobotic surgery leadership and resilient procedure demand support premium forward growth.
Future value: $362.62 (+18.45%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Strong Buy consensus and Barclays Buy rating.
- ▸Above 50-day MA (+3.72%)
Is SYK a buy right now?
Trend: SYK is trading above the 50-day average (+3.84%), RSI 58 — neutral momentum, with a 3-month return of -8.79%.
Valuation & quality: Stryker Corporation trades on a trailing P/E of 31.7, forward P/E 18.4, PEG 1.44, price-to-book 4.90; fundamentals show net margin 14.4%, return on equity 16.5%, revenue growth 9.4% year on year.
Analyst consensus: 26 analysts have a mean 12-month price target of $362.62 (+18.5% vs the last close; range $298.00 – $465.00), consensus rating “buy”.
Income: trailing dividend yield 1.15%.
Our screen: BUY (score 3) — Robotic surgery leadership and resilient procedure demand support premium forward growth.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -15.20% | -4.10% | -3.20% | +3.20% | +3.40% | -0.60% | -15.00% | +11.50% |
Fundamentals
Analyst price target
Technical signals
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Sector: Healthcare · Industry: Medical Devices · United States · 56,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.